These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
234 related articles for article (PubMed ID: 21738572)
1. Designing nanoconjugates to effectively target pancreatic cancer cells in vitro and in vivo. Khan JA; Kudgus RA; Szabolcs A; Dutta S; Wang E; Cao S; Curran GL; Shah V; Curley S; Mukhopadhyay D; Robertson JD; Bhattacharya R; Mukherjee P PLoS One; 2011; 6(6):e20347. PubMed ID: 21738572 [TBL] [Abstract][Full Text] [Related]
2. Targeting Pancreatic Cancer Cells and Stellate Cells Using Designer Nanotherapeutics in vitro. Elechalawar CK; Hossen MN; Shankarappa P; Peer CJ; Figg WD; Robertson JD; Bhattacharya R; Mukherjee P Int J Nanomedicine; 2020; 15():991-1003. PubMed ID: 32103952 [TBL] [Abstract][Full Text] [Related]
3. Nanoconjugation modulates the trafficking and mechanism of antibody induced receptor endocytosis. Bhattacharyya S; Bhattacharya R; Curley S; McNiven MA; Mukherjee P Proc Natl Acad Sci U S A; 2010 Aug; 107(33):14541-6. PubMed ID: 20679244 [TBL] [Abstract][Full Text] [Related]
4. Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent. Patra CR; Bhattacharya R; Wang E; Katarya A; Lau JS; Dutta S; Muders M; Wang S; Buhrow SA; Safgren SL; Yaszemski MJ; Reid JM; Ames MM; Mukherjee P; Mukhopadhyay D Cancer Res; 2008 Mar; 68(6):1970-8. PubMed ID: 18339879 [TBL] [Abstract][Full Text] [Related]
5. Noninvasive radiofrequency field-induced hyperthermic cytotoxicity in human cancer cells using cetuximab-targeted gold nanoparticles. Curley SA; Cherukuri P; Briggs K; Patra CR; Upton M; Dolson E; Mukherjee P J Exp Ther Oncol; 2008; 7(4):313-26. PubMed ID: 19227011 [TBL] [Abstract][Full Text] [Related]
6. A comparative analysis of EGFR-targeting antibodies for gold nanoparticle CT imaging of lung cancer. Ashton JR; Gottlin EB; Patz EF; West JL; Badea CT PLoS One; 2018; 13(11):e0206950. PubMed ID: 30408128 [TBL] [Abstract][Full Text] [Related]
7. Gold nanoparticles and radiofrequency in experimental models for hepatocellular carcinoma. Raoof M; Corr SJ; Zhu C; Cisneros BT; Kaluarachchi WD; Phounsavath S; Wilson LJ; Curley SA Nanomedicine; 2014 Aug; 10(6):1121-30. PubMed ID: 24650884 [TBL] [Abstract][Full Text] [Related]
8. Switching the targeting pathways of a therapeutic antibody by nanodesign. Bhattacharyya S; Singh RD; Pagano R; Robertson JD; Bhattacharya R; Mukherjee P Angew Chem Int Ed Engl; 2012 Feb; 51(7):1563-7. PubMed ID: 22135077 [No Abstract] [Full Text] [Related]
9. Lack of in vivo antibody dependent cellular cytotoxicity with antibody containing gold nanoparticles. Ahmed M; Pan DW; Davis ME Bioconjug Chem; 2015 May; 26(5):812-6. PubMed ID: 25879583 [TBL] [Abstract][Full Text] [Related]
10. Folate-Gold-Bilirubin Nanoconjugate Induces Apoptotic Death in Multidrug-Resistant Oral Carcinoma Cells. Rathinaraj P; Muthusamy G; Prasad NR; Gunaseelan S; Kim B; Zhu S Eur J Drug Metab Pharmacokinet; 2020 Apr; 45(2):285-296. PubMed ID: 31858458 [TBL] [Abstract][Full Text] [Related]
11. Multifunctional gold-nanoparticles: A nanovectorization tool for the targeted delivery of novel chemotherapeutic agents. Fernandes AR; Jesus J; Martins P; Figueiredo S; Rosa D; Martins LM; Corvo ML; Carvalheiro MC; Costa PM; Baptista PV J Control Release; 2017 Jan; 245():52-61. PubMed ID: 27871990 [TBL] [Abstract][Full Text] [Related]
12. Use of Biocompatible Sorafenib-gold Nanoconjugates for Reversal of Drug Resistance in Human Hepatoblatoma Cells. Vishwakarma SK; Sharmila P; Bardia A; Chandrakala L; Raju N; Sravani G; Sastry BVS; Habeeb MA; Khan AA; Dhayal M Sci Rep; 2017 Aug; 7(1):8539. PubMed ID: 28819176 [TBL] [Abstract][Full Text] [Related]
13. Noninvasive radiofrequency field destruction of pancreatic adenocarcinoma xenografts treated with targeted gold nanoparticles. Glazer ES; Zhu C; Massey KL; Thompson CS; Kaluarachchi WD; Hamir AN; Curley SA Clin Cancer Res; 2010 Dec; 16(23):5712-21. PubMed ID: 21138869 [TBL] [Abstract][Full Text] [Related]
14. Enhanced cytotoxic activity of cetuximab in EGFR-positive lung cancer by conjugating with gold nanoparticles. Qian Y; Qiu M; Wu Q; Tian Y; Zhang Y; Gu N; Li S; Xu L; Yin R Sci Rep; 2014 Dec; 4():7490. PubMed ID: 25502402 [TBL] [Abstract][Full Text] [Related]
15. Inhibiting the growth of pancreatic adenocarcinoma in vitro and in vivo through targeted treatment with designer gold nanotherapeutics. Kudgus RA; Szabolcs A; Khan JA; Walden CA; Reid JM; Robertson JD; Bhattacharya R; Mukherjee P PLoS One; 2013; 8(3):e57522. PubMed ID: 23483913 [TBL] [Abstract][Full Text] [Related]
16. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting. Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436 [TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo antitumor activity of cetuximab in human gastric cancer cell lines in relation to epidermal growth factor receptor (EGFR) expression and mutational phenotype. Hotz B; Keilholz U; Fusi A; Buhr HJ; Hotz HG Gastric Cancer; 2012 Jul; 15(3):252-64. PubMed ID: 22011788 [TBL] [Abstract][Full Text] [Related]
18. Synthesis, Characterization and Anti-Cancer Therapeutic Potential of Withanolide-A with 20nm sAuNPs Conjugates Against SKBR3 Breast Cancer Cell Line. Tabassam Q; Mehmood T; Raza AR; Ullah A; Saeed F; Anjum FM Int J Nanomedicine; 2020; 15():6649-6658. PubMed ID: 32982224 [TBL] [Abstract][Full Text] [Related]
19. Biological characterization of cetuximab-conjugated gold nanoparticles in a tumor animal model. Kao HW; Lin YY; Chen CC; Chi KH; Tien DC; Hsia CC; Lin WJ; Chen FD; Lin MH; Wang HE Nanotechnology; 2014 Jul; 25(29):295102. PubMed ID: 24990295 [TBL] [Abstract][Full Text] [Related]
20. Targeted Delivery of Cisplatin by Gold Nanoparticles: The Influence of Nanocarrier Surface Modification Type on the Efficiency of Drug Binding Examined by CE-ICP-MS/MS. Wróblewska AM; Milewska A; Drozd M; Matczuk M Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216438 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]